AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+46.42%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$502M
AUM Growth
+$502M
(+64%)
Cap. Flow
+$75.9M
Cap. Flow
% of AUM
15.13%
Top 10 Holdings %
Top 10 Hldgs %
46.98%
Holding
91
New
13
Increased
21
Reduced
21
Closed
11
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$41.6M |
| 2 |
LIAN
LianBio American Depositary Shares
LIAN
|
$13.9M |
| 3 |
Celldex Therapeutics
CLDX
|
$9.92M |
| 4 |
Nuvalent
NUVL
|
$9.2M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$7.35M |
Top Sells
| 1 |
Apogee Therapeutics
APGE
|
$14.2M |
| 2 |
Kura Oncology
KURA
|
$9.56M |
| 3 |
Tourmaline Bio
TRML
|
$8.69M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$6.57M |
| 5 |
Cytokinetics
CYTK
|
$5.87M |
Sector Composition
| 1 | Healthcare | 94.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $41.6M | 7.61% | +1,404,608 | New | +$41.6M |
|
|
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $31.8M | 5.81% | 750,000 +64,939 | +9% | +$2.75M |
|
|
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
| $25.8M | 4.7% | 1,090,441 -38,935 | -3% | -$920K |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $23.1M | 4.23% | 100,000 +15,000 | +18% | +$3.47M |
|
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $21.2M | 3.87% | 460,000 +159,562 | +53% | +$7.35M |
|
6
Teva Pharmaceuticals
TEVA
$21.1B
| $19.8M | 3.62% | 1,900,000 -100,000 | -5% | -$1.04M |
|
7
Arcellx
ACLX
$3.85B
| $18.9M | 3.45% | 340,000 -60,000 | -15% | -$3.33M |
|
|
LIAN
8
DELISTED
LianBio American Depositary Shares
LIAN
| $16.9M | 3.09% | 3,779,694 +3,107,337 | +462% | +$13.9M |
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $15.9M | 2.91% | 447,095 -2,905 | -0.6% | -$103K |
|
|
10
Celldex Therapeutics
CLDX
$1.47B
| $15.9M | 2.9% | 400,000 +250,000 | +167% | +$9.92M |
|
|
11
Apogee Therapeutics
APGE
$2.17B
| $15M | 2.74% | 537,093 -508,017 | -49% | -$14.2M |
|
12
Immunovant
IMVT
$2.56B
| $14.5M | 2.65% | 345,000 +45,000 | +15% | +$1.9M |
|
|
13
Cytokinetics
CYTK
$4.23B
| $13.4M | 2.44% | 160,000 -70,366 | -31% | -$5.87M |
|
|
14
Nuvalent
NUVL
$5.52B
| $12.9M | 2.35% | 175,000 +125,000 | +250% | +$9.2M |
|
15
Astria Therapeutics
ATXS
$349M
| $11.3M | 2.06% | 1,466,465 +466,165 | +47% | +$3.58M |
|
|
VRNA
16
Verona Pharma
VRNA
$9.16B
| $11.2M | 2.05% | 563,824 +195,495 | +53% | +$3.89M |
|
17
Spyre Therapeutics
SYRE
$996M
| $11.1M | 2.03% | 517,554 +275,257 | +114% | +$5.92M |
|
|
AUTL
18
Autolus Therapeutics
AUTL
$399M
| $9.98M | 1.82% | 1,550,408 -442,058 | -22% | -$2.85M |
|
19
Alkermes
ALKS
$4.78B
| $9.89M | 1.81% | 356,384 +256,384 | +256% | +$7.11M |
|
|
INZY
20
DELISTED
Inozyme Pharma
INZY
| $8.03M | 1.47% | 1,885,802 +505,950 | +37% | +$2.16M |
|
21
Nurix Therapeutics
NRIX
$714M
| $7.12M | 1.3% | 690,112 +440,112 | +176% | +$4.54M |
|
|
CNTA
22
Centessa Pharmaceuticals
CNTA
$2.25B
| $6.33M | 1.16% | 795,729 -222,362 | -22% | -$1.77M |
|
23
Establishment Labs
ESTA
$1.2B
| $5.91M | 1.08% | 228,277 -10,831 | -5% | -$280K |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.88M | 1.07% | 100,049 +39,623 | +66% | +$2.33M |
|
25
Roivant Sciences
ROIV
$8.15B
| $5.62M | 1.03% | 500,000 +350,000 | +233% | +$3.93M |
|